July 14, 2010 – Devicor Medical Products Inc. announced this week the company completed the acquisition of Ethicon Endo-Surgery’s (EES) breast care business. The division sells products designed to help doctors diagnose breast cancer at early stages while minimizing patient discomfort. The business will formally be known as Mammotome, a division of Devicor.
The EES breast care product portfolio is sold in 50 countries around the world and includes the Mammotome Breast Biopsy System and tissue markers (MammoMARK, MicroMARK, and CorMARK) used for breast disease diagnostic sampling and management. As part of the agreement, Devicor also acquired marketing and distribution rights for Neoprobe Gamma Detection Systems.
Mammotome’s corporate headquarters will be located in Sharonville, Ohio. Recently, the company was awarded a 60 percent job creation tax credit for seven years, valued at $1.5 million, from the Ohio Department of Development.
Now that the transaction is complete, nearly 300 EES associates primarily dedicated to the breast care business will be hired by Mammotome. Mammotome’s plans for growth include adding more than 150 jobs worldwide, of which approximately 70 positions will be located at the corporate headquarters. In addition, Mammotome plans to build a new manufacturing plant in the next 12 to 18 months.
April 16, 2024 
